Proteo Biotech

What Proteo Biotech does

Tiakis Biotech AG (referenced as Proteo Biotech in some sources) is a privately held, clinical-stage biotechnology company headquartered in Kiel, Germany. Founded in 2000, the company is singularly focused on developing Tiprelestat, an investigational anti-inflammatory and tissue-protective drug designed to leverage the body's own protective mechanisms. The company is pursuing two therapeutic indications: Pulmonary Arterial Hypertension (PAH), a debilitating and rapidly progressive rare disease with high unmet medical need for disease-modifying therapies, and prevention of postoperative inflammatory complications in patients undergoing highly invasive surgery.

Tiprelestat represents the company's sole core product and is grounded in more than 20 years of clinical research. The company maintains a focused R&D model with academic and clinical partnerships spanning Stanford University, the University of Edinburgh, and the University Hospital Schleswig-Holstein (UKSH), supported by government funding from Germany's Federal Ministry of Education and Research (BMBF) and regional development agency WTSH.

As a pre-commercial entity, Tiakis Biotech generates no product revenue. The business model relies on research grants, government funding, and presumably private capital to sustain clinical development. Future revenue mechanics are contingent on regulatory approval of Tiprelestat, after which commercial distribution would likely rely on traditional pharmaceutical channels including specialty pharmacies and hospital pharmacies targeting the rare disease population. Customer-facing operations are limited to clinical trial distribution through academic medical centers.

Name

Proteo Biotech

Legal name

tiakis BIOTECH AG

Website

https://proteo.de

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Tiakis Biotech AG is a Kiel-based, clinical-stage biotech developing Tiprelestat, an investigational anti-inflammatory and tissue-protective drug targeting pulmonary arterial hypertension and postoperative inflammatory complications, sustained through academic partnerships and government research funding.

Ownership category

akta.pro rank

Product category

Pulmonary Hypertension Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Rare disease therapeutics
• Anti-inflammatory drug development
• Pulmonary hypertension treatment
• Clinical stage biotechnology
• Biopharmaceutical research

Headquarters

HQ city

Kiel

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels1 record

Core offering

Proteo Biotech is a clinical-stage biopharmaceutical company developing Tiprelestat, an investigational anti-inflammatory and tissue-protective drug designed as a disease-modifying therapy for Pulmonary Arterial Hypertension (PAH) and for the prevention of postoperative inflammatory complications following highly invasive surgery. The therapy leverages the body's own protective mechanisms and is backed by more than 20 years of clinical research.

Product overview

tiakis BIOTECH AG is developing a single therapeutic product: Tiprelestat. This investigational drug is a pioneering anti-inflammatory and tissue protective therapy targeting Pulmonary Arterial Hypertension and postoperative inflammatory complications. The company is focused on developing this disease modifying therapy utilizing the body's own protective mechanisms based on more than 20 years of clinical research.

Differentiator

Problem solved

Functional benefit

Products and services

• Tiprelestat An investigational anti-inflammatory and tissue-protective drug being developed as a disease-modifying therapy for Pulmonary Arterial Hypertension (PAH), a rapidly progressive rare disease, and for the prevention of postoperative inflammatory complications in patients undergoing highly invasive surgery. The drug utilizes the body's own natural defense mechanisms.

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Stanford UniversitycoreStrategic or Co-development PartnerAcademic research partnership with Stanford University for the development of Tiprelestat. Stanford is listed among the company's partners, indicating collaboration in research and clinical development activities.
• University of EdinburghcoreStrategic or Co-development PartnerAcademic research partnership with University of Edinburgh for the development of Tiprelestat. The partnership contributes to the company's more than 20 years of clinical research utilizing the body's own protective mechanisms.
• UKSH (University Hospital Schleswig-Holstein)coreStrategic or Co-development PartnerPartnership with University Hospital Schleswig-Holstein for clinical research and development activities. Located in the same region as the company's headquarters in Kiel, facilitating close collaboration.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Emerging players

• Pliant Therapeutics: Pliant is a clinical-stage biotech developing integrin-based therapies for fibrotic lung diseases including IPF. Comparable as a small US biotech focused on inflammatory/fibrotic pulmonary indications.
• Silence Therapeutics: Silence Therapeutics is a European clinical-stage biotech developing siRNA-based therapies. Comparable as a small European public/private biotech with a platform mechanism applied to specialty disease indications.
• Gossamer Bio: Gossamer Bio is a clinical-stage biotech with seralutinib in Phase 3 for PAH. Direct therapeutic-area competitor with a similarly sized development pipeline pursuing a mechanism-driven PAH therapy.
• Liquidia Corporation: Liquidia develops nebulized treprostinil for PAH and PH-ILD using PRINT particle technology. Comparable as a small-cap clinical developer of improved-delivery PAH drugs.
• Insmed: Insmed is a mid-cap biotech with PAH/PAH-ILD programs (e.g., treprostinil palmitil) using proprietary inhaled delivery. Comparable as a rare respiratory disease specialist advancing improved PAH therapeutics.
• Aerovate Therapeutics: Aerovate Therapeutics is a clinical-stage US biotech developing an inhaled dry-powder imatinib for PAH. Highly comparable as a small, focused PAH drug developer competing for the same disease-modifying positioning as Tiprelestat.

Broad incumbents

• Acceleron Pharma (a Merck company): Acceleron developed sotatercept (Winrevair) for PAH, recently acquired by Merck. Comparable as an emerging modality in PAH that frames the competitive landscape Tiprelestat will enter.
• Actelion Pharmaceuticals (Janssen / Johnson & Johnson): Actelion (now part of Janssen/J&J) built and still dominates the PAH market with Tracleer, Uptravi, and Opsumit. Comparable as the established incumbent in the indication Tiprelestat seeks to disrupt.

Direct peers

• United Therapeutics: United Therapeutics is a market leader in PAH with a portfolio of approved prostacyclin-based therapies (Tyvaso, Remodulin). Direct comparable because it targets the same PAH patient population that Tiakis' Tiprelestat aims to address as a disease-modifying alternative.

Others

• Bayer AG: Bayer is a large German pharmaceutical company with a cardiovascular and pulmonary pipeline and historical experience in PAH drug development. Listed as a potential strategic acquirer/partner for a German investigational-stage biotech like Tiakis.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/proteo-biotech-ag

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proteo Biotech